Biocon’s EBITDA up by 36 per cent

Biocon Ltd. announces its results for Q4FY16. Consolidated Net Income from Operations  has risen by around 20 per cent and stands at Rs 641 crore as compared to the previous quarter were it stood at Rs 533 crore. Quarterly EBITDA margin has also seen a double digit jump. EBITDA has increased by 36 per cent and stands at Rs 115.6 crore. Net Profit for the quarter ended has created history; Net profit for Q4FY16 has increased 2 times as compared to previous quarter. Net profit stands at Rs 138.2 crore.

On a YoY basis the Net Income from Operation stands at Rs 978.8 crore as compared to the Rs 836.4 crore for the previous year. Net Income from Operation has increased by 17 per cent. EBITDA margin has also seen an increase of 13 per cent and stands at Rs 213.1 crore. Net Profits on a YoY basis stand at Rs 383.8 crore as compared to 121.1 crore, which means that profits on a YoY basis have increased three times to the previous year.

Biocon’s reason behind a double digit profit is fairly because of increase in other income. Increase in other income has increased by 25 per cent and stands at Rs 24.7 crore (YoY). The company is majorly a non cyclical company and therefore there is very less risk and effects of external environment. The shares on exchanges were trading at Rs 571.35 and have increased by 6 per cent on an intra-day basis.

Biocon Limited is a fully integrated global healthcare company that delivers bio pharmaceutical solutions. The company offers a range of products from fermentation derived small molecules to recombinant proteins and antibodies. The company also offers custom bio-manufacturing services to domestic and international pharmaceutical companies.